10

Contrast Medium-Induced Nephropathy (CIN) Gram-Iodine/GFR Ratio to Predict CIN and Strategies to Reduce Contrast Medium Doses

Ulf Nyman
Lund University
Sweden

1. Introduction

Radiographic iodine contrast media (I-CM) has been recognized as the third leading cause of hospital-acquired renal insufficiency or the most common cause among pharmaceutical agents (Nash et al., 2002) with an overall incidence of contrast medium-induced nephropathy (CIN) of 1-2% following percutaneous coronary angiography (PCA) and interventions (PCI) (Mehran & Nikolsky, 2006). The presence of multiple CIN risk factors or high-risk clinical scenarios may create a substantial risk of CIN (≈50%), acute renal failure (≈15%) requiring dialysis and an increased morbidity and mortality (Marenzi et al., 2004; McCullough et al., 2006a, 2006b). At the same time it has been argued that the risk of CIN is lower following IV administration of CM in connection with computed tomography (CT) than after IA injections during cardiac procedures (Davidson et al., 2006; Katzberg & Barrett, 2007; Katzberg & Newhouse, 2010), though there exist no comparative studies based on matched risk factors and CM doses.

Reliable prediction of pre-procedural renal function, identification of CIN risk factors, institution of adequate prophylactic regimens and to modify examination technique to reduce CM-dose are crucial to reduce patient suffering and cost since curative treatment is not available. A wide spectrum of CIN risk factors including high age, diabetes mellitus, poor cardiac function, and hemodynamic instability has been thoroughly outlined in recent reviews (McCullough et al., 2006b; Mehran & Nikolsky, 2006).

A number of prophylactic regimen studies has been performed and meta-analyzed (Kelly et al., 2008). So far no adjunctive medical pharmacological treatment has convincingly been proved to be efficacious in reducing the risk of CIN (Stacul et al., 2006) including acetylcysteine (Biondi-Zoccai et al., 2006) and hydration with sodium bicarbonate instead of saline (Zoungas et al., 2009). Haemodialysis is ineffective and hemofiltration is impractical in routine clinical practice (Stacul et al., 2006).

Thus, treating modifiable risk factors (Mehran & Nikolsky, 2006), instituting adequate intravenous volume expansion with isotonic crystalloid (Stacul et al., 2006) and withdrawal of nephrotoxic drugs, mannitol and loop diuretics are three of the four corner stones to reduce the risk of CIN (Thomsen et al., 2008a). The fourth one is to minimize the dose of the

offending agent itself, i.e. the contrast medium (Davidson et al., 2006; Kane et al., 2008; Sterner et al., 2001). Though low- and iso-osmolal CM should be substituted for high-osmolal CM (Barrett & Carlisle, 1993; Rudnick et al., 1995), the benefit of iso- over low-osmolal CM is only suggestive but not statistically significant according to a recent meta-analysis (From et al., 2010).

The present chapter will focus on:

- The risk of CIN in IV versus IA CM administration.
- Using estimated glomerular filtration rate (eGFR) in absolute terms to evaluate renal function.
- Using gram iodine (g-I) to express CM-dose instead of simply volumes and promoting g-I/eGFR ratio to maximize CM doses as a predictor of CIN instead of the Cigarroa formula (Cigarroa et al., 1989).
- Potential means to reduce CM dose for CT coronary angiography (CTCA) in patients at risk of CIN.
- The potential of using iodine concentrations and doses iso-attenuating with gadolinium (Gd) CM and other means to decrease CM-doses in patients at risk of CIN.

2. IV versus IA CM administration and CIN

The alleged lower risk of CIN following CM-enhanced CT compared with PCA/PCI has lead to conclusions such as

- "In clinical settings such as CM-enhanced multidetector CT makes it defensible to consider using CM even in patients with greater levels of background risk factors (e.g. greater degree of preexisting chronic renal insufficiency) than one would be comfortable with in the IA setting" (Katzberg & Barrett, 2007) and
- "International radiologic professional organizations should revisit the basis of their practice guidelines to reduce their implications about the danger of CIN with CM-enhanced CT"s (Katzberg & Newhouse, 2010).

Such statements and conclusions may jeopardize patient safety, since they were not based on any studies comparing the risk of CIN following CM-enhanced CT and coronary interventions in patients with matched risk factors and CM-doses. In addition, a recent study showed no difference in the incidence of CIN between CT-angiography and digital subtraction angiography (DSA) of the aortofemoral arteries in the same patients. The lack of difference occurred despite that the DSA-results may have been affected by the CM load from the CT performed 3-14 days prior to the DSA (Karlsberg et al., 2011).

It seems inexplicable that the same type of CM molecules passing through the coronary arteries via the coronary sinus to the right atrium should be more nephrotoxic than if the same molecules pass via the arm veins to the right atrium and then through the pulmonary circulation to finally reach the kidneys via the aorta. As a matter of fact in the vast majority of IA injections, the CM has to pass through the venous system before reaching the kidneys (IV relative to the kidneys), i.e. carotid, subclavian, celiac, mesenteric, distal aortic and iliaco-femoral. Left ventriculography or aortography in connection with PCA/PCI is an exception. However, in this case only a minor part will reach the kidneys directly through the aortic route, i.e. about 20% of cardiac output or e.g. 2-3 grams of iodine following a left

ventriculography (6-8 mL of an injected volume of 30-40 mL of 320 to 370 mg I/mL) of a total mean dose commonly ranging between 50 to 100 grams of iodine during a coronary procedures. Spill-over into the aorta also occurs during selective coronary artery injections and through side-holes of guiding catheters during PCI. However, the amount during each injection is so small that it will hardly affect plasma osmolality to cause any hypertonic renal effects and will therefore only affect the kidneys with the same pathophysiological mechanisms as an IV injection will do.

In the relatively few published reports of CIN following CM-enhanced CT the incidence may vary between 0 and 42% depending on definitions, degree of renal impairment and number and degree of risk factors (Katzberg & Newhouse, 2010; Nguyen et al., 2008; Polena et al., 2005; Tepel et al., 2000; Thomsen et al., 2008b). In a recent prospective study of unselected emergency patients 11% (n=70/633) increased their serum creatinine ≥44 μmol/L or ≥25% of whom 9% (n=6) developed CM-induced severe renal failure, which contributed to death in 4 of the 6 patients (Mitchell et al., 2010). Another CIN study showed that IV CM injections were actually associated with a higher mortality risk than IA administration (From et al., 2008). One explanation may be that the entire CM dose in CT is injected within one minute and thus may strike the kidneys at a considerable higher dose rate compared with a coronary arterial procedure that may last for 15-30-60 minutes or even longer.

It should also be noted that in randomized studies comparing renal effects of various CM, high-risk patients (e.g. unstable renal function, heart failure, uncontrolled diabetes, recent CM examinations, etc.) are often excluded (Barrett et al., 2006; Kuhn et al., 2008; Nguyen et al., 2008; Thomsen et al., 2008b). This bias in patient selection compared with coronary studies, where high-risk patients can not be excluded from life-saving procedures, may in part explain the illusive opinion that an IV CM injection implies a lesser risk of CIN than an IA. Thus, it may seem premature to consider the risk of CIN less following IV injections than after IA administration.

3. Evaluation of renal function

It is well recognized that serum creatinine is a poor predictor of renal function (Perrone et al., 1992), especially in elderly patients with decreasing muscle mass, the major source of creatinine. In one study 50% of patients ≥70 years with a normal serum creatinine had a GFR ≤50 mL/min (Duncan et al., 2001).

Measurement of GFR based on exogenous markers such as inulin and I-CM is regarded the best indices of the level of renal function in health and disease (Stevens et al., 2006), but is work-intensive, relatively expensive, time-consuming and therefore unsuitable in clinical practice prior to CM administration. Instead, GFR should be estimated (eGFR) taking into account not only serum creatinine but also anthropometric (weight and height) and/or demographic (gender and age) data as a measure of muscle mass by using dedicated GFR prediction equations (Stevens et al., 2006) such as the MDRD (Modification of Diet in Renal Disease) (Levey et al., 2007), CKD-EPI (Levey et al., 2009) and Lund-Malmö equations (Nyman et al., 2006). Consequently, newly developed CIN risk scores include eGFR using prediction equations (Bartholomew et al., 2004; Mehran et al., 2004). Before adapting a GFR prediction equation the following should be considered:

- The creatinine assay in the local laboratory must be calibrated according to the specific method used when the equation was developed, in practice isotope dilution mass spectrometry (IDMS) with modern equations (Myers et al., 2006).
- Dosing of drugs excreted by glomerular filtration should be based on GFR not adjusted for body surface area, i.e. absolute GFR in mL/min (Stevens et al., 2009). GFR adjusted to body surface area, i.e. relative GFR in mL/min/1.73 m^2, will overestimate actual GFR in small subjects, especially children, and underestimate it in large individuals. The MDRD and CKD-EPI equations primarily gives relative GFR, which can be converted to absolute GFR using a body surface area equation such as the commonly used Dubois formula (Dubois & Dubois, 1916 (DuBois & DuBois, 1916):

$$\text{Body surface area } (m^2) = \text{weight}^{0.425} \times (\text{height}^{0.725}) \times 0.007184$$

  with weight expressed in kg and height in cm.
- Estimated GFR is only within 30% of measured GFR in 80-85% of the patients (Levey et al., 2009; Nyman et al., 2006). Thus, a patient with eGFR of 50 mL/min may actually only have a real GFR of 35 mL/min.

4. Systemic drug exposure, gram-iodine/eGFR ratio and CIN

4.1 Area under the plasma concentration-time curve (AUC)

Following injection of CM, blood samples may be used to calculate AUC. It is directly proportional to CM dose and inversely correlated with GFR (Frennby & Sterner, 2002). AUC is a fundamental pharmacokinetic parameter used to estimate *systemic exposure* of drugs that are distributed and eliminated according to linear kinetics, like contrast media (Chen et al., 2001; Sherwin et al., 2005). The systemic exposure of such a drug is often well correlated with its *toxicity* and hence is generally held as an index for dose optimization (Chen et al., 2001). The clinical value of AUC as a predictor of nephrotoxicity has been shown for a variety of drugs and CM dose/GFR ratio was first proposed as a potential indicator for the risk of CIN in 1997 (Altmann et al., 1997) and later in 2005 (Nyman et al., 2005; Sherwin et al., 2005).

4.2 Gram-iodine/eGFR ratio

CM doses in CIN risk scores and recommendations to minimize the risk of CIN have for obscure reasons often been based only on volumes (Bartholomew et al., 2004; Davidson et al., 2006; Mehran et al., 2004). It should rather be expressed in terms of gram iodine (g-I) since concentrations of commercially available CM varies from 140-400 mg I/mL and it will also reflect the attenuating capacity. This also makes it easier to compare CM doses and expand the experience of CIN made from one examination or department to another if different concentrations are used. Furthermore, common g-I doses for radiography-based procedures, i.e. 10-120 g-I, are in the same numerical range as patients' GFR, i.e. 10-120 mL/min. Thus, forming a g-I/eGFR ratio combines CM volume and concentration, serum creatinine, age and body size into a single continuous risk variable, and provides the examiner with a simple numerical relationship and an expedient way to predict the risk of CIN. This implies also a more sophisticated relationship between CM dose and renal function than the Cigarroa formula (Cigarroa et al., 1989) that lacks CM concentration and

uses serum creatinine instead of GFR; i.e. maximum CM volume = 5 mL × body weight/serum creatinine (mg/dL). From a female perspective, with a possible increased CIN-risk compared with males (Brown et al., 2008), the g-I/eGFR ratio is preferable since creatinine-based GFR prediction equation also contains coefficients for female gender, which is lacking in the Cigarroa formula.

Mounting evidence from coronary interventions indicate that a g-I/eGFR ratio roughly >1.0 represent a significant and independent predictor of CIN (Table 1). At a g-I/GFR ratio <1.0 the reported CIN frequency was <3% (Gurm et al, 2011; Laskey et al, 2007; Nyman et al, 2008).

First author, year	Number	Indication	Volume/ eGFR ratio	Iodine Concentration (mg I/mL)	g-I/eGFR ratio
Laskey, 2007	3179	Unselected population	3.7	350[2]	1.30[5]
Nyman, 2008	391	STEMI	2.9[1]	350	1.00
Nozue, 2009	60	Stable angina	5.1	370	1.89[5]
Worasuwannarak, 2010	248	Elective diabetics	2.60	370[3]	0.98
Mager, 2010	871	STEMI	3.7	370	1.37[5]
Liu et al, 2011	277	STEMI	2.39	370[4]	0.88[5]
Total	5026				
Weighted mean value			3.50		1.24

Table 1. Gram-iodine/eGFR ratio and CIN in coronary interventions. Studies defining CM-volume/eGFR ratio or gram-iodine/eGFR ratio as a significant and independent predictor of CIN (serum creatinine rise ≥25% or ≥44 μmol/L above baseline). Weighted mean value with individual study sizes as weights were finally calculated based on log-transformation of volume/eGFR and g-I/eGFR ratio. Absolute GFR was estimated in 3 reports (Laskey et al., 2007; Nyman et al., 2008; Worasuwannarak & Pornratanarangsi, 2010) and relative GFR in the remaining.
1. Calculated from the g-I/eGFR ratio and iodine concentration.
2. Anticipated mean concentration.
3. 96% 370 mg I/mL and 4% 320 mg I/mL (e-mail communication with the authors).
4. 271 patients 370 mg I/mL and 6 patients 320 mg I/mL (e-mail communication with the authors).
5. Calculated from the volume/eGFR ratio and iodine concentration.

A most recently published registry study involving about 50,000 patients recommended a planned gram-iodine dose restricted to 0.7 x eGFR value and not to exceed 1.0 x eGFR if a CM concentration of 350 mg I/mL for PCI is anticipated (Gurm et al., 2011).

Using a g-I/eGFR <1.0 implies a safer maximum dose compared with the Cigarroa formula. A 60-year old female with a height of 160 cm, weight 70 kg and serum creatinine of 150

μmol/mL (1.7 mg/dL) results in an eGFR of 31 mL/min if the IDMS-traceable MDRD equation is used (Levey et al., 2007). At a CM concentration of 350 mg I/mL, 31 grams of iodine will give a maximum CM volume of 88 mL (31,000/350). The corresponding figures in a male will be 41 grams of iodine and 118 mL. According to the Cigarroa formula the maximum volume will be 206 mL ($5 \times 70/1.7$) for both females and males.

Individual patient data from CT studies are lacking, but weighted mean data from CT-studies shows an 8% incidence of CIN at a g-I/eGFR ratio of 0.9 (Table 2), indicating that the ratio should also be kept <1.0 also at CT.

First author, year	Type of CM	N	CM dose (gram iodine)	eGFR ([A]mL/min or [R]mL/min/1.73 m^2)	g-I/eGFR ratio	CIN (%)
Tepel, 2000[1]	LOCM	42	23	[A]34	0.7	21
Lufft, 2002	LOCM	33	49	[A]63	0.8	9.1
Kolehemainen, 2003	LOCM/IOCM	50	35	[?]29	1.2	16
Garcia-Ruiz, 2004	LOCM	50	48	[A]30	1.6	4.0
Becker, 2005	LOCM	100	27	[R]41	0.7	9.0
Barrett, 2006	LOCM/IOCM	150	40	[A]45	1.0[2]	3.9
Thomsen, 2008b[3]	LOCM/IOCM	148	40	[A]42	1.0	6.1
Nguyen, 2008	LOCM	56	37	[A]53	0.7	28
Kuhn, 2008	LOCM/IOCM	248	36	[R]49	0.7	5.2
Weisbord, 2008	LOCM	421	48	[R]53	0.9	6.5
Total		1301				
Weighted mean data			40	47	0.9	7.8

Table 2. Gram-iodine/eGFR ratio and CIN in CT studies. Literature review of non-randomized and randomized CT-studies reporting mean gram-iodine dose (or volume and concentration), mean eGFR (A = absolute GFR, R = relative GFR), g-I/eGFR ratio (calculated by the author) and incidence of CIN (serum creatinine rise ≥25% or ≥44 μmol/L above baseline). Only results for low-osmolal contrast media (LOCM) included unless there was no significant difference between LOCM and IOCM (iso-osmolal contrast media). Weighted mean value with individual study sizes as weights were finally calculated. The weighted mean of the g-I/eGFR ratio was based on log-transformation.
1. Only control group not receiving acetylcysteine included
2. Based on individual data in the report
3. Based on the CIN definition ≥25% serum creatinine increase

Note that if GFR adjusted to body surface area is used to form the g-I/GFR ratio, a higher maximum dose may be permitted in small individuals while large individuals may tolerate a larger dose certain ratio would indicate. In addition analyzing g-I/GFR ratio as a

significant independent predictor of CIN may give erroneous results. Half of the reports in Table 1 used relative eGFR (Liu et al., 2011; Mager et al., 2010; Nozue et al., 2009) and three of the ten studies in Table 2.

If a CM-based examination is deemed necessary in high risk patients, the author's strategy is to keep the g-I/GFR ratio as low as reasonably achievable, preferably below 0.5. Features classifying a patient at high risk of CIN (Kakkar et al., 2008; Mehran et al., 2004) may include:

- GFR <40 mL/min OR
- CIN risk score ≥16 (Table 3) or ≥three risk factors OR
- Congestive heart failure (NYHA III/IV) OR
- Multiple CM exposures within 72 hours

Risk factors	Integer score
Hypotension (<80 mm Hg for at least 1 h requiring inotropic support or intra-aortic balloon pump within 24 h periprocedurally)	5
Intra-aortic balloon pump	5
Congestive heart failure (New York Heart Association III/IV)	5
Age >75 years	4
Anemia (hematocrit value <39% for men and <36% for women)	3
Diabetes mellitus	3
Contrast medium volume	1 for each 100 mL
Serum creatinine >133 μmol/L (1.5 mg/dL)	4
GFR <60 mL/min/1.73 m² 40-60 20-40 <20	2 4 6

Table 3. Mehran CIN risk score (Mehran et al., 2004).

5. Reducing CM doses in CT-angiography of azotemic patients

During the past decade, CTCA has become a clinical reality as a consequence of major advances in CT technology. Vascular enhancement in CT-angiography is dependent on a number of factors such as CM dose, injection rate, plasma volume, cardiac output (CO) and x-ray tube potential (Bae & Heiken, 2005; Fleischmann, 2003; Kormano et al., 1983; Kristiansson et al., 2010).

5.1 CM distribution volume and injected dose rate

The distribution volume of CM includes the plasma volume and the extravascular extracellular space, both related to body weight. By dosing CM in relation to body weight

and using a fixed injection duration adapted to scan time, a fixed injected dose rate (mg I/kg/s) is obtained and vascular enhancement becomes essentially unrelated to body size (Awai et al., 2004a). When these principles are used, the choice of CM concentration is of no concern regarding CM enhancement (Awai et al., 2004b; Suzuki et al., 2004).

It may be anticipated that fixed CM doses irrespective of body weight have been adjusted to provide a proper enhancement in larger patients. Thus, dosing per kg implies that the risk of CIN may at least be reduced for low weight patients for the same enhancement as in a larger patient. In fact CM doses regarded sufficient for 80-100 kg patients could be halved for 40-50 kg patients to obtain the same degree of enhancement. A maximum dosing weight of 80-90 kg may be chosen, assuming that higher weights in most patients correspond to adipose tissue with minimal contribution to the distribution volume of CM.

Calculation of individual CM volumes and injection rates based on CM dose in milligram iodine/kg, concentration and injection duration can be easily done with a Microsoft Excel spreadsheet or using a dedicated computer program developed to calculate both eGFR and CM injection parameters from predefined CT protocols (OmniVis, GE Healthcare, Stockholm, Sweden).

5.2 Cardiac output and vascular CM enhancement

Arterial enhancement increases with decreasing CO (Bae et al., 1998) due to less dispersion and dilution of the CM bolus and at the same time poor cardiac function is an independent risk factor of CIN. Renal impairment may induce cardiac dysfunction and vice versa, the so called cardiorenal syndrome (Ronco et al., 2008). Since increasing age also predispose to decreasing renal function and cardiac diseases, many azotemic patients will have a reduced CO. Thus, it would be possible to decrease CM dose in most azotemic patients for the same vascular CM-enhancement as that obtained in patients with normal cardiac function. On the other hand a patient with no CIN risk factors and hyperkinetic circulation may need and tolerate a higher CM dose than normal to achieve diagnostic quality without jeopardizing renal function.

Since cardiac function may play a major role for CM-enhancement in CTCA and echocardiography results may be readily available in coronary patients, information of cardiac function should be used when tailoring the CM protocol. Another option is to use electrical velocimetry to measure CO, readily performed in the CT suite (Flinck et al., 2010). This has the advantage that measured CO will reflect cardiac function at the time of the CM injection. CO measured by echocardiography hours to days prior to CTCA may result in inadequate CM injection parameters, since CO is highly dependent on pulse rate and may vary considerably for number a of reasons.

5.3 X-ray tube potential and iodine attenuation

Attenuation of photons by iodine is highly dependent on the x-ray spectra used. As an example decreasing the x-ray tube peak kilovoltage (kVp) from commonly used 120 kVp for CT to 80 kVp brings the x-ray spectra closer to the k-edge of iodine (33.2 keV) and increases iodine attenuation by a factor 1.6 (Prokop, 2003). Thus, the CM dose may be reduced by a factor 1.6 while maintaining the attenuation at the same level as that obtained at 120 kVp.

However, the effective x-ray tube loading in terms of milliampere seconds (mAs) has to be increased by a factor four to keep image noise constant and results in 50% increase in radiation dose for the same reference object (Holmquist et al., 2009; Kristiansson et al., 2010). Thus, the diagnostic quality in terms of contrast-to-noise ratio (CNR) may be preserved. The increased radiation dose and risk of cancer induction may be of less concern in elderly azotemic patients with coronary artery disease and a limited survival time than the risk of CIN.

5.4 Halved CM doses at CT-angiography in azotemic patients

By combining CM dose tailored to body weight, a fixed injection time adapted to scan time, automatic bolus tracking, saline chaser, x-ray tube potential of 80 kVp and anticipating a decreased cardiac output in azotemic patients, it has been possible to halve the CM dose from 300 mg I/kg at 120 kVp and to 150 mg I/kg at 80 kVp when performing 16-row detector pulmonary CT-angiography in patients with eGFR <50 mL/min (Kristiansson et al., 2010). The median g-I/eGFR ratio was 0.3 and no CIN episodes were recorded. A total median dose of 10 grams of iodine was used, which is only 20-40% of non-body size related CM doses reported by those using 16-row detector for pulmonary CT-angiography at 120-140 kVp (Bae et al., 2005; Holmquist et al., 2009; Holmquist & Nyman, 2006; Johnson et al., 2007).

These principles should also be possible to adopt when performing CTCA in patients at high risk of CIN, especially with today's CT-equipments with many more detector rows, more potent x-ray tubes and dual energy options.

6. Percutaneous coronary angiography and interventions

The risk of CIN is related to the CM dose (Davidson et al., 2006; Freeman et al., 2002; Marenzi et al., 2009). Though there are numerous prophylactic studies on pharmacological agents, with hardly any unequivocally positive prophylactic effects so far (Stacul et al., 2006), studies on technical aspects of how to minimize the CM dose in coronary procedures are conspicuous by their almost total absence.

The average CM dose at PCA and/or PCI may range from 40 to 110 grams of iodine (Aspelin et al., 2003; Davidson et al., 2000; Laskey et al., 2007; Marenzi et al., 2009; Nyman et al., 2008; Rudnick et al., 1995; Worasuwannarak & Pornratanarangsi, 2010), while individual doses may range from 10 to inconceivable 500 grams of iodine (Marenzi et al., 2009).

In a Letter to the Editor Kane et al. (2008) reported on utilizing biplane angiography for PCA resulting in a mean CM dose of only 8 grams of iodine (25 mL 320 mg I/mL), half the dose used for monoplane. Despite a higher CIN risk profile among patients examined with biplane, the incidence of CIN was significantly lower compared with those studied with monoplane. Freeman et al. (2002) proposed guidelines for high-risk patients including determination of the "maximum allowed radiocontrast dose", limit necessary images (i.e. left ventriculogram or other images) and excessive "puffs", and whenever possible consider staged diagnostic and therapeutic procedures with several days in between. Another option to reduce CM dose is to use a lower concentration than the perfunctory 320 to 370 mg I/mL as discussed below.

6.1 Iodine concentration iso-attenuating with gadolinium CM

Attenuation increases with the atomic number (Z) of the atom (iodine, Z = 53; gadolinium, Z = 64). At photon energies between the k-edge of iodine (33.2 keV) and that of gadolinium (50.2 keV), iodine attenuates roughly twice as many photons as does gadolinium (Nyman et al., 2002). At all other photon energies the opposite prevail. Thus, a gadolinium (Gd) CM may be used as an x-ray CM. Before the advent of nephrogenic systemic fibrosis (NSF) (Thomsen, 2009), some investigators reported on the use of Gd-CM in a variety of diagnostic angiographic and interventional procedures (Spinosa et al., 2002; Strunk & Schild, 2004) including PCA (Barcin et al., 2006; Briguori et al., 2006; Gupta & Uretsky, 2005; Sarkis et al., 2003; Voss et al., 2004) in patients at risk of CIN due to its perceived non-nephrotoxicity (Prince et al., 1996). However, the non-nephrotoxicity of Gd-CM has been proved wrong (Buhaescu & Izzedine, 2008; Ergun et al., 2006; Sam et al., 2003). In fact, Gd-CM may have a higher, both general and renal, toxicity than I-CM in concentrations and volumes causing the same attenuation as Gd-CM (Elmståhl et al., 2004; Elmståhl et al., 2008; Nyman et al., 2002).

Moreover, the maximum dose of Gd-CM according to the manufacturers' recommendations is only 0.2-0.3 mmol/kg, though average doses used for x-ray angiographic procedures have ranged from 0.2-0.8 mmol/kg. However, average clinical I-CM doses of 40-100 grams of iodine, results in about 4-10 mmol/kg in a 75 kg individual. Thus, the use of Gd-CM is limited in terms of volume and radiodensity (Nyman et al., 2011). Despite this, diagnostic satisfactory PCA has been achieved with 1.0M Gd-CM (Briguori et al., 2006; Voss et al., 2004) or 2:1 (Barcin et al., 2006; Sarkis et al., 2003) and 1:1 mixtures (Gupta & Uretsky, 2005) of 0.5M Gd-CM and I-CM.

Angiographic experiments with a 30 cm thick water-equivalent phantom at 70 and 95 kVp indicate that iodine concentrations at 60 and 80 mg/mL, respectively, are iso-attenuating with 0.5M Gd-CM (Nyman et al., 2011). The attenuation of the 1.0M Gd-CM and the mixtures between 0.5M Gd-CM and I-CM at 320 or 350 mg I/mL would correspond to about 140-200 mg I/mL of a pure I-CM at 70-95 kVp, concentrations that are commercially available. Thus, it seems possible to perform coronary procedures with half or even one third of the standard concentrations, not at least in thinner patients patients in whom automatic or manual down-regulation of the x-ray tube potential will increase attenuation by iodine.

Precautions and techniques to save contrast media during PCA/PCI in azotemic patients are summarized as follows:

- If possible, delay examination, treat risk factors and institute hydration.
- Substitute echocardiography for left ventriculography.
- Use biplane technique if available.
- Consider to use commercially available concentrations in the range of 140-200 mg I/mL, especially in thinner patients.
- Avoid excessive "puffs" and scrutinize each series before the next one to avoid unnecessary standard projections.
- Substitute measurements with pressure wires of indeterminate stenotic lesions for multiple projections.

- Whenever possible consider staged diagnostic and therapeutic procedures with several days in between.

7. Conclusion

- Scientific evidence is lacking regarding the opinion that IV administration of CM should be less nephrotoxic than IA administration.
- Renal function should be estimated taking into account not only serum creatinine but also anthropometric (weight and height) and/or demographic (gender and age) by using dedicated GFR prediction equations.
- CM dose should be expressed in grams of iodine instead of simply volumes since it also takes into account concentration and serves as an index of diagnostic capacity.
- A g-I/eGFR ratio ≥1.0 appears to a significant and independent predictor of CIN in coronary interventions but it may also be valid for CT-angiography.
- If a CM examination is deemed necessary in patients at high risk of CIN, the author's goal is to keep the dose as low as reasonably achievable, preferably below a g-I/eGFR ratio of 0.5, which may be possible by applying a meticulous examination technique and the following CM doses and concentrations:
  - CT-angiography: 100-150 mg I/kg by using 80 kVp, mAs-compensation for constant CNR, fixed injection duration adapted to scan time, automatic bolus tracking and a saline chaser.
  - Coronary arteriography and interventions: 140-200 mg I/mL, especially in thinner patients in whom automatic or manual down-regulation of the x-ray tube potential will increase iodine attenuation.

8. References

Altmann DB, Zwas D, Spatz A, Bergman G, Spokojny A, Riva S, Sanborn TA (1997). Use of the contrast volume estimated creatinine clearance ratio to predict renal failure after angiography. *J Interv Cardiol,* Vol.10, pp. 113-119

Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ (2003). Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med,* Vol.348, No.6, (2003 Feb 6), pp. 491-499, ISSN 1533-4406 (Electronic)

Awai K, Hiraishi K, Hori S (2004a). Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. *Radiology,* Vol.230, No.1, (2004 Jan), pp. 142-150, ISSN 0033-8419 (Print)

Awai K, Inoue M, Yagyu Y, Watanabe M, Sano T, Nin S, Koike R, Nishimura Y, Yamashita Y (2004b). Moderate versus high concentration of contrast material for aortic and hepatic enhancement and tumor-to-liver contrast at multi-detector row CT. *Radiology,* Vol.233, No.3, (2004 Dec), pp. 682-688, ISSN 0033-8419 (Print)

Bae KT, Heiken JP (2005). Scan and contrast administration principles of MDCT. *Eur Radiol,* Vol.15(Suppl 5), pp. E46-E59

Bae KT, Heiken JP, Brink JA (1998). Aortic and hepatic contrast medium enhancement at CT. Part II. Effect of reduced cardiac output in a porcine model. *Radiology,* Vol.207, No.3, (1998 Jun), pp. 657-662, ISSN 0033-8419 (Print)

Bae KT, Mody GN, Balfe DM, Bhalla S, Gierada DS, Gutierrez FR, Menias CO, Woodard PK, Goo JM, Hildebolt CF (2005). CT depiction of pulmonary emboli: display window settings. *Radiology,* Vol.236, No.2, (2005 Aug), pp. 677-684, ISSN 0033-8419 (Print)

Barcin C, Kursaklioglu H, Iyisoy A, Kose S, Tore HF, Isik E (2006). Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography. *Heart Vessels,* Vol.21, No.3, (2006 May), pp. 141-145, ISSN 0910-8327 (Print)

Barrett BJ, Carlisle EJ (1993). Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology,* Vol.188, No.1, (1993 Jul), pp. 171-178, ISSN 0033-8419 (Print)

Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Nelson R (2006). Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. *Invest Radiol,* Vol.41, No.11, (2006 Nov), pp. 815-821, ISSN 0020-9996 (Print)

Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW (2004). Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol,* Vol.93, No.12, (2004 Jun 15), pp. 1515-1519, ISSN 0002-9149 (Print)

Becker CR, Reiser MF (2005). Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. *Invest Radiol,* Vol.40, No.10, (2005 Oct), pp. 672-675, ISSN 0020-9996 (Print)

Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F, Valgimigli M, Romagnoli E, Crea F, Agostoni P (2006). Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. *BMJ,* Vol.332, No.7535, (Jan 28), pp. 202-209, ISSN 1468-5833 (Electronic), 0959-535X (Linking)

Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, Montorfano M, Chieffo A, Bellanca R, Ricciardelli B (2006). Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. *Catheter Cardiovasc Interv,* Vol.67, No.2, (2006 Feb), pp. 175-180, ISSN 1522-1946 (Print)

Brown JR, DeVries JT, Piper WD, Robb JF, Hearne MJ, Ver Lee PM, Kellet MA, Watkins MW, Ryan TJ, Silver MT, Ross CS, MacKenzie TA, O'Connor GT, Malenka DJ (2008). Serious renal dysfunction after percutaneous coronary interventions can be predicted. *Am Heart J,* Vol.155, No.2 pp. 260-266, ISSN 1097-6744 (Electronic), 0002-8703 (Linking)

Buhaescu I, Izzedine H (2008). Gadolinium-induced nephrotoxicity. *Int J Clin Pract,* Vol.62, No.7, (2008 Jul), pp. 1113-1118, ISSN 1742-1241 (Electronic), 1368-5031 (Linking)

Chen M-L, Lekso L, Williams R (2001). Measures of exposure versus measures of rate and extent of absorption. *Clin Pharmacokinet,* Vol.40, pp. 565-572

Cigarroa RG, Lange RA, Williams RH, Hillis LD (1989). Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. *Am J Med,* Vol.86, No.6 Pt 1, (1989 Jun), pp. 649-652, ISSN 0002-9343 (Print)

Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W, Jr., Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW, Jr.

(2000). Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. *Circulation,* Vol.101, No.18 pp. 2172-2177, ISSN 1524-4539 (Electronic), 0009-7322 (Linking)

Davidson CJ, Stacul F, McCullough PA, Tumlin J, Adam A, Lameire N, Becker CR (2006). Contrast medium use. *Am J Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 42K-58K, ISSN 0002-9149 (Print)

DuBois D, DuBois E (1916). A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med,* Vol.17, pp. 863-871

Duncan L, Heathcote J, Djurdjev O, Levin A (2001). Screening for renal disease using serum creatinine: who are we missing? *Nephrol Dial Transplant,* Vol.16, No.5, (2001 May), pp. 1042-1046, ISSN 0931-0509 (Print)

Elmståhl B, Nyman U, Leander P, Chai CM, Frennby B, Almén T (2004). Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. *Acad Radiol,* Vol.11, No.11, (2004 Nov), pp. 1219-1228, ISSN 1076-6332 (Print)

Elmståhl B, Nyman U, Leander P, Golman K, Chai CM, Grant D, Doughty R, Pehrson R, Bjork J, Almen T (2008). Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys. *Radiology,* Vol.247, No.1, (2008 Apr), pp. 88-97, ISSN 1527-1315 (Electronic)

Ergun I, Keven K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O (2006). The safety of gadolinium in patients with stage 3 and 4 renal failure. *Nephrol Dial Transplant,* Vol.21, No.3, (2006 Mar), pp. 697-700, ISSN 0931-0509 (Print)

Fleischmann D (2003). Use of high-concentration contrast media in multiple-detector-row CT: principles and rationale. *Eur Radiol,* Vol.13 Suppl 5, (2003 Dec), pp. M14-20, ISSN 0938-7994 (Print)

Flinck M, Graden A, Milde H, Flinck A, Hellstrom M, Bjork J, Nyman U (2010). Cardiac output measured by electrical velocimetry in the CT suite correlates with coronary artery enhancement: a feasibility study. *Acta Radiol,* Vol.51, No.8, (Oct), pp. 895-902, ISSN 1600-0455 (Electronic), 0284-1851 (Linking)

Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, DeFranco AC, Eagle KA, McGinnity JG, Patel K, Maxwell-Eward A, Bondie D, Moscucci M (2002). Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. *Am J Cardiol,* Vol.90, No.10 pp. 1068-1073, ISSN 0002-9149 (Print), 0002-9149 (Linking)

Frennby B, Sterner G (2002). Contrast media as markers of GFR. *Eur Radiol,* Vol.12, No.2, (2002 Feb), pp. 475-484, ISSN 0938-7994 (Print)

From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS (2010). Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. *Circ Cardiovasc Interv,* Vol.3, No.4 pp. 351-358, ISSN 1941-7632 (Electronic), 1941-7640 (Linking)

From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS (2008). Mortality associated with nephropathy after radiographic contrast exposure. *Mayo Clin Proc,* Vol.83, No.10, (2008 Oct), pp. 1095-1100, ISSN 1942-5546 (Electronic)

Garcia-Ruiz C, Martinez-Vea A, Sempere T, Sauri A, Olona M, Peralta C, Oliver A (2004). Low risk of contrast nephropathy in high-risk patients undergoing spiral computed

tomography angiography with the contrast medium iopromide and prophylactic oral hydratation. *Clin Nephrol,* Vol.61, No.3, (Mar), pp. 170-176, ISSN 0301-0430 (Print), 0301-0430 (Linking)

Gupta R, Uretsky BF (2005). Gadodiamide-based coronary angiography in a patient with severe renal insufficiency. *J Interv Cardiol,* Vol.18, No.5, (2005 Oct), pp. 379-383, ISSN 0896-4327 (Print)

Gurm HS, Dixon SR, Smith DE, Share D, LaLonde T, Greenbaum A, Moscucci M (2011). Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol,* Vol.58, pp. 907-914.

Holmquist F, Hansson K, Pasquariello F, Bjork J, Nyman U (2009). Minimizing Contrast Medium Doses to Diagnose Pulmonary Embolism with 80-kVp Multidetector Computed Tomography in Azotemic Patients. *Acta Radiol,* Vol.50, (2009 Jan 23), pp. 181-193, ISSN 1600-0455 (Electronic)

Holmquist F, Nyman U (2006). Eighty-peak kilovoltage 16-channel multidetector computed tomography and reduced contrast-medium doses tailored to body weight to diagnose pulmonary embolism in azotaemic patients. *Eur Radiol,* Vol.16, No.5, (2006 May), pp. 1165-1176, ISSN 0938-7994 (Print)

Johnson PT, Naidich D, Fishman EK (2007). MDCT for suspected pulmonary embolism: multi-institutional survey of 16-MDCT data acquisition protocols. *Emerg Radiol,* Vol.13, No.5, (2007 Feb), pp. 243-249, ISSN 1070-3004 (Print)

Kakkar R, Sobieszczyk P, Binkert CA, Faxon DP, Mortele KJ, Singh AK (2008). Prevention of intravenous contrast-induced nephropathy in hospital inpatients. *Crit Pathw Cardiol,* Vol.7, No.1, (Mar), pp. 1-4, ISSN 1535-2811 (Electronic), 1535-2811 (Linking)

Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS (2008). Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. *J Am Coll Cardiol,* Vol.51, No.1, (2008 Jan 1), pp. 89-90, ISSN 1558-3597 (Electronic), 0735-1097 (Linking)

Karlsberg RP, Dohad SY, Sheng R (2011). Contrast Medium-induced Acute Kidney Injury: Comparison of Intravenous and Intraarterial Administration of Iodinated Contrast Medium. *J Vasc Interv Radiol*, pp. 1-7, Epub ahead of print, doi: 10.1016/j.jvir.2011.03.020, ISSN 1535-7732 (Electronic), 1051-0443 (Linking)

Katzberg RW, Barrett BJ (2007). Risk of iodinated contrast material--induced nephropathy with intravenous administration. *Radiology,* Vol.243, No.3, (2007 Jun), pp. 622-628, 0033-8419 (Print)

Katzberg RW, Newhouse JH (2010). Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? *Radiology,* Vol.256, No.1, (Jul), pp. 21-28, ISSN 1527-1315 (Electronic), 0033-8419 (Linking)

Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008). Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med,* Vol.148, No.4, (2008 Feb 19), pp. 284-294, ISSN 1539-3704 (Electronic)

Kolehemainen H, Sovia M (2003). Comparison of Xenetix 300 and Visipaque 320 in patients with renal failure (P27). 10th European Symposium on Urogenital Radiology. *Euro Radiol,* Vol.13, pp. B32-B33

Kormano M, Partanen K, Soimakallio S, Kivimaki T (1983). Dynamic contrast enhancement of the upper abdomen: effect of contrast medium and body weight. *Invest Radiol,* Vol.18, No.4, (1983 Jul-Aug), pp. 364-367, ISSN 0020-9996 (Print)

Kristiansson M, Holmquist F, Nyman U (2010). Ultralow contrast medium doses at CT to diagnose pulmonary embolism in patients with moderate to severe renal impairment. A feasibility study. *Eur Radiol,* Vol.20, No.6, pp. 1321-1330

Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ (2008). The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. *AJR Am J Roentgenol,* Vol.191, No.1, (2008 Jul), pp. 151-157, ISSN 1546-3141 (Electronic)

Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, Cohen HA, Holmes DR, Jr. (2007). Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. *J Am Coll Cardiol,* Vol.50, No.7, (2007 Aug 14), pp. 584-590, ISSN 1558-3597 (Electronic)

Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F (2007). Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem,* Vol.53, No.4, (2007 Apr), pp. 766-772, ISSN 0009-9147 (Print)

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009). A new equation to estimate glomerular filtration rate. *Ann Intern Med,* Vol.150, No.9, (2009 May 5), pp. 604-612, ISSN 1539-3704 (Electronic), 1539-3704 (Linking)

Liu Y, Tan N, Zhou YL, He PC, Luo JF, Chen JY (2011). The contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention. *Int Urol Nephrol*, (Feb 20), Epub ahead of print, doi:10.1007/s11255-11011-19910-11254, ISSN 1573-2584 (Electronic), 0301-1623 (Linking)

Lufft V, Hoogestraat-Lufft L, Fels LM, Egbeyong-Baiyee D, Tusch G, Galanski M, Olbricht CJ (2002). Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. *Am J Kidney Dis,* Vol.40, No.2, (Aug), pp. 236-242, ISSN 1523-6838 (Electronic), 0272-6386 (Linking)

Mager A, Assa HV, Lev EI, Bental T, Assali A, Kornowski R (2010). The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. *Catheter Cardiovasc Interv*, (Oct 14), Epub ahead of print, doi: 10.1002/ccd.22828, ISSN 1522-726X (Electronic), 1522-1946 (Linking)

Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL (2009). Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. *Ann Intern Med,* Vol.150, No.3 pp. 170-177, ISSN 1539-3704 (Electronic), 0003-4819 (Linking)

Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL (2004). Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol,* Vol.44, No.9, (2004 Nov 2), pp. 1780-1785, ISSN 0735-1097 (Print)

McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J (2006a). Epidemiology and prognostic implications of contrast-induced nephropathy. *Am J Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 5K-13K, ISSN 0002-9149 (Print)

McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J (2006b). Risk prediction of contrast-induced nephropathy. *Am J Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 27K-36K, ISSN 0002-9149 (Print)

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G (2004). A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol,* Vol.44, No.7, (2004 Oct 6), pp. 1393- ISSN 1399, 0735-1097 (Print)

Mehran R, Nikolsky E (2006). Contrast-induced nephropathy: definition, epidemiology, and patients at risk. *Kidney Int Suppl,* Vol.69, No.100, (2006 Apr), pp. S11-15, ISSN 0098-6577 (Print)

Mitchell AM, Jones AE, Tumlin JA, Kline JA (2010). Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. *Clin J Am Soc Nephrol,* Vol.5, No.1 pp. 4-9, ISSN 1555-905X (Electronic), 1555-9041 (Linking)

Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH (2006). Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clin Chem,* Vol.52, No.1, (2006 Jan), pp. 5-18, ISSN 0009-9147 (Print)

Nash K, Hafeez A, Hou S (2002). Hospital-acquired renal insufficiency. *Am J Kidney Dis,* Vol.39, No.5, (2002 May), pp. 930-936, ISSN 1523-6838 (Electronic)

Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, Costello P, Schoepf UJ (2008). Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. *Radiology,* Vol.248, No.1, (2008 Jul), pp. 97-105, ISSN 1527-1315 (Electronic)

Nozue T, Michishita I, Iwaki T, Mizuguchi I, Miura M (2009). Contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy developing after elective percutaneous coronary intervention. *J Cardiol,* Vol.54, No.2, (Oct), pp. 214-220, ISSN 1876-4738 (Electronic), 0914-5087 (Linking)

Nyman U, Almen T, Aspelin P, Hellström M, Kristiansson M, Sterner G (2005). Contrast-medium-Induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. *Acta Radiol,* Vol.46, No.8, (2005 Dec), pp. 830-842, ISSN 0284-1851 (Print)

Nyman U, Björk J, Aspelin P, Marenzi G (2008). Contrast medium dose-to-GFR ratio: A measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. *Acta Radiol* Vol.49, pp. 658-667,

Nyman U, Björk J, Sterner G, Bäck SE, Carlson J, Lindström V, Bakoush O, Grubb A (2006). Standardization of p-creatinine assays and use of lean body mass allow improved prediction of calculated glomerular filtration rate in adults: a new equation. *Scand J Clin Lab Invest,* Vol.66, No.6, (2006), pp. 451-468, ISSN 0036-5513 (Print)

Nyman U, Elmstahl B, Geijer H, Leander P, Almen T, Nilsson M (2011). Iodine contrast iso-attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients? *Eur Radiol,* Vol.21, (Aug 29), pp. 326-336, ISSN 1432-1084 (Electronic), 0938-7994 (Linking)

Nyman U, Elmståhl B, Leander P, Nilsson M, Golman K, Almén T (2002). Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? *Radiology,* Vol.223, No.2, (2002 May), pp. 311-318; discussion 328-319, ISSN 0033-8419 (Print)

Perrone RD, Madias NE, Levey AS (1992). Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem,* Vol.38, No.10, (1992 Oct), pp. 1933-1953, ISSN 0009-9147 (Print)

Polena S, Yang S, Alam R, Gricius J, Gupta JR, Badalova N, Chuang P, Gintautas J, Conetta R (2005). Nephropathy in critically Ill patients without preexisting renal disease. *Proc West Pharmacol Soc,* Vol.48, (2005), pp. 134-135, ISSN 0083-8969 (Print)

Prince MR, Arnoldus C, Frisoli JK (1996). Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. *J Magn Reson Imaging,* Vol.6, No.1, (1996 Jan-Feb), pp. 162-166, ISSN 1053-1807 (Print), 1053-1807 (Linking)

Prokop M (2003). Image analysis In: *Spiral and multislice computed tomography of the body.* Prokop M, Galanski M, Van der Molen AJ, Schaefer-Prokop C, Thieme, ISBN 3-13-116481-6, Stuttgart

Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008). Cardiorenal syndrome. *J Am Coll Cardiol,* Vol.52, No.19, (Nov 4), pp. 1527-1539, ISSN 1558-3597 (Electronic), 0735-1097 (Linking)

Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB (1995). Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. *Kidney Int,* Vol.47, No.1, (1995 Jan), pp. 254-261, ISSN 0085-2538 (Print)

Sam AD, 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003). Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. *J Vasc Surg,* Vol.38, No.2, (2003 Aug), pp. 313-318, ISSN 0741-5214 (Print)

Sarkis A, Badaoui G, Azar R, Sleilaty G, Bassil R, Jebara VA (2003). Gadolinium-enhanced coronary angiography in patients with impaired renal function. *Am J Cardiol,* Vol.91, No.8, (2003 Apr 15), pp. 974-975, A974, ISSN 0002-9149 (Print)

Sherwin PF, Cambron R, Johnson JA, Pierro JA (2005). Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radiocontrast-induced nephropathy: correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol. *Invest Radiol,* Vol.40, No.9, (2005 Sep), pp. 598-603, ISSN 0020-9996 (Print)

Spinosa DJ, Angle JF, Hartwell GD, Hagspiel KD, Leung DA, Matsumoto AH (2002). Gadolinium-based contrast agents in angiography and interventional radiology. *Radiol Clin North Am,* Vol.40, No.4, (2002 Jul), pp. 693-710, ISSN 0033-8389 (Print), 0033-8389 (Linking)

Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J (2006). Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol,* Vol.98, No.6A, (2006 Sep 18), pp. 59K-77K, ISSN 0002-9149 (Print)

Sterner G, Nyman U, Valdes T (2001). Low risk of contrast-medium-induced nephropathy with modern angiographic technique. *J Intern Med,* Vol.250, No.5, (2001 Nov), pp. 429-434, ISSN 0954-6820 (Print), 0954-6820 (Linking)

Stevens LA, Coresh J, Greene T, Levey AS (2006). Assessing kidney function--measured and estimated glomerular filtration rate. *N Engl J Med,* Vol.354, No.23, (2006 Jun 8), pp. 2473-2483, ISSN 1533-4406 (Electronic)

Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS (2009). Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. *Am J Kidney Dis,* Vol.54, No.1 pp. 33-42, ISSN 1523-6838 (Electronic), 0272-6386 (Linking)

Strunk HM, Schild H (2004). Actual clinical use of gadolinium-chelates for non-MRI applications. *Eur Radiol,* Vol.14, No.6, (2004 Jun), pp. 1055-1062, ISSN 0938-7994 (Print), 0938-7994 (Linking)

Suzuki H, Oshima H, Shiraki N, Ikeya C, Shibamoto Y (2004). Comparison of two contrast materials with different iodine concentrations in enhancing the density of the the aorta, portal vein and liver at multi-detector row CT: a randomized study. *Eur Radiol,* Vol.14, No.11, (2004 Nov), pp. 2099-2104, ISSN 0938-7994 (Print)

Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000). Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med,* Vol.343, No.3, (Jul 20), pp. 180-184, ISSN 0028-4793 (Print), 0028-4793 (Linking)

Thomsen HS (2009). Nephrogenic systemic fibrosis: history and epidemiology. *Radiol Clin North Am,* Vol.47, No.5, (2009 Sep), pp. 827-831, ISSN 1557-8275 (Electronic), 1557-8275 (Linking)

Thomsen HS, Morcos SK, Almén T, Aspelin P, Liss P, Bellin M-F, Oyen R, den Braber ET, Flaten H, Idée J-M, Löwe A, Jakobsen JÅ, Spinazzi A, Stacul F, Webb JA, van der Molen A (2008a). European Society of Urogenital Radiology Contrast Media Safety Committee. ESUR guidelines on contrast media version 7.0. 23.06.2011, Available from http://www.esur.org

Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L (2008b). The ACTIVE Trial: Comparison on the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. *Invest Radiol,* Vol.43, pp. 170-178

Voss R, Grebe M, Heidt M, Erdogan A (2004). Use of gadobutrol in coronary angiography. *Catheter Cardiovasc Interv,* Vol.63, No.3, (2004 Nov), pp. 319-322, ISSN 1522-1946 (Print)

Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ (2008). Incidence and outcomes of contrast-induced AKI following computed tomography. *Clin J Am Soc Nephrol,* Vol.3, No.5, (2008 Sep), pp. 1274-1281, ISSN 1555-905X (Electronic)

Worasuwannarak S, Pornratanarangsi S (2010). Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio. *J Med Assoc Thai,* Vol.93 Suppl 1, (Jan), pp. S29-34, ISSN 0125-2208 (Print), 0125-2208 (Linking)

Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, Patel A, Vasheghani-Farahani A, Sadigh G, Perkovic V (2009). Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. *Ann Intern Med,* Vol.151, No.9, (Nov 3), pp. 631-638, ISSN 1539-3704 (Electronic), 0003-4819 (Linking)



Coronary Interventions

Edited by Dr. Neville Kukreja

ISBN 978-953-51-0498-8
Hard cover, 244 pages
Publisher InTech
Published online 18, April, 2012
Published in print edition April, 2012

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Ulf Nyman (2012). Contrast Medium-Induced Nephropathy (CIN) Gram-Iodine/GFR Ratio to Predict CIN and Strategies to Reduce Contrast Medium Doses, Coronary Interventions, Dr. Neville Kukreja (Ed.), ISBN: 978-953-51-0498-8, InTech, Available from: http://www.intechopen.com/books/coronary-interventions/strategies-to-avoid-contrast-medium-induced-nephropathy-

INTECH
open science | open minds

InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

IntechOpen